Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Author:

Dimopoulos Meletios A.1,Palumbo Antonio2,Corradini Paolo3,Cavo Michele4,Delforge Michel5,Di Raimondo Francesco6,Weisel Katja C.7,Oriol Albert8,Hansson Markus9,Vacca Angelo10,Blanchard María Jesús11,Goldschmidt Hartmut12,Doyen Chantal13,Kaiser Martin14,Petrini Mario15,Anttila Pekka16,Cafro Anna Maria17,Raymakers Reinier18,San-Miguel Jesus19,de Arriba Felipe20,Knop Stefan21,Röllig Christoph22,Ocio Enrique M.23,Morgan Gareth24,Miller Neil25,Simcock Mathew25,Peluso Teresa25,Herring Jennifer26,Sternas Lars26,Zaki Mohamed H.26,Moreau Philippe27

Affiliation:

1. National and Kapodistrian University of Athens, Athens, Greece,

2. University of Turin, Turin, Italy;

3. University of Milan, Fondazione IRCCS Istituto Nazionale de Tumori, Milan, Italy;

4. Bologna University School of Medicine, Bologna, Italy;

5. University Hospital Leuven, Leuven, Belgium;

6. University of Catania, Catania, Italy;

7. University Hospital of Tuebingen, Tuebingen, Germany;

8. Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;

9. Skane University Hospital, Lund University, Lund, Sweden;

10. University of Bari Medical School, Bari, Italy;

11. Hospital Ramón y Cajal, Madrid, Spain,

12. University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany,

13. Université Catholique de Louvain, Centre Hospitalier Universitaire, Université Catholique de Louvain Namur, Yvoir, Belgium;

14. The Royal Marsden Hospital, Surrey, United Kingdom;

15. Santa Chiara Hospital, University of Pisa, Pisa, Italy;

16. Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland;

17. Hospedale Niguarda Ca' Granda, Milan, Italy;

18. University Medical Center Utrecht, Utrecht, The Netherlands;

19. Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain;

20. Hospital General Universitario Morales Meseguer, Murcia, Spain;

21. Wurzburg University Medical Center, Wurzburg, Germany;

22. Universitatsklinikum, Medizinsche Klinik und Poliklinik I, Dresden, Germany;

23. Complejo Asistencial Universitario de Salamanca Centro Investigación del Cáncer–Instituto de Biología Molecular y Celular del Cancer) Cancer Research Center, Salamanca, Spain;

24. Myeloma Institute for Research and Therapy, University of Arkansas Medical School, Little Rock, AR;

25. Celgene International Sàrl, Boudry, Switzerland;

26. Celgene Corporation, Summit, NJ; and

27. University Hospital Hotel‐Dieu, Nantes, France

Abstract

Key Points STRATUS (MM-010), the largest POM + LoDEX trial, confirms the regimen offers clinically meaningful benefit and is generally well tolerated. STRATUS supports POM + LoDEX as a standard of care for patients with RRMM who have poor prognosis and high need for effective treatments.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3